VRAX (Virax Biolabs Group) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 07, 2026)


VRAX Virax Biolabs Group Ltd VRAX
37 GF Score
Price $3.09
GF Value $1.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Virax Biolabs Group Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Virax Biolabs Group's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

VRAX vs BBLG, PKTX, OGEN: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Virax Biolabs Group's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Margin of Safety % (DCF Dividends Based) falls into.


VRAX
37GF Score
Virax Biolabs Group Ltd VRAX
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15. GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.

Key valuation signals for VRAX:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score

Get the complete analysis for VRAX

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price
$1.15
GF Value